Cytovale Company Profile

Background

Cytovale is a commercial-stage medical diagnostics company headquartered in San Francisco, California. The company is dedicated to advancing early detection technologies for diagnosing rapidly progressing and immune-mediated diseases, with a primary focus on sepsis—a leading cause of mortality in U.S. hospitals. Cytovale's mission is to improve patient outcomes by providing healthcare professionals with rapid, accurate diagnostic tools that facilitate timely and effective treatment decisions.

Key Strategic Focus

Cytovale's strategic focus centers on the development and commercialization of innovative diagnostic solutions that address critical unmet needs in emergency medicine. The company's flagship product, IntelliSep®, is an FDA-cleared rapid diagnostic test designed for early detection of sepsis in emergency department (ED) settings. By leveraging advanced microfluidics and machine learning technologies, IntelliSep provides actionable results in approximately eight minutes, enabling clinicians to make informed decisions swiftly and improve patient care.

Financials and Funding

Cytovale has successfully secured substantial funding to support its growth and commercialization efforts:

Series B Financing (October 2019): Raised $15 million, comprising $7.4 million in equity financing co-led by Breakout Ventures and Blackhorn Ventures, and a $7.6 million partnership with the U.S. Department of Health and Human Services' Biomedical Advanced Research and Development Authority (BARDA).

Series C Financing (November 2023): Secured $84 million led by Norwest Venture Partners, with participation from Sands Capital and Global Health Investment Corporation.

Series D Financing (October 2024): Raised $100 million led by Sands Capital, with contributions from new investor Canada Pension Plan Investment Board (CPP Investments) and existing investors.

The cumulative funding of $199 million is allocated towards expanding the commercial reach of IntelliSep, enhancing manufacturing capabilities, and supporting ongoing research and development initiatives.

Pipeline Development

Cytovale's primary product, IntelliSep, is a rapid diagnostic test that assesses a patient's probability of developing sepsis within three days. The test has been implemented in various hospital systems, including the Franciscan Missionaries of Our Lady Health System (FMOLHS), where it has demonstrated significant clinical and operational benefits. These include a 30% reduction in the risk-adjusted mortality index for sepsis patients and a decrease in hospital length of stay by 1.28 days per patient tested.

Technological Platform and Innovation

Cytovale's IntelliSep test distinguishes itself through several proprietary technologies and methodologies:

Microfluidics and Deformability Cytometry: Utilizes advanced microfluidic techniques to apply physical pressure to white blood cells, assessing their mechanical properties to detect immune system dysregulation indicative of sepsis.

Machine Learning Algorithms: Employs sophisticated machine learning models to analyze cellular responses, enabling rapid and accurate risk stratification of patients based on their likelihood of developing sepsis.

Leadership Team

Cytovale's leadership comprises experienced professionals with diverse backgrounds:

Ajay Shah, Ph.D. – Co-founder and Chief Executive Officer. Dr. Shah has a background in biomedical engineering and has been instrumental in guiding Cytovale's strategic direction and product development.

Christopher Slachta – Chief Operating Officer. Appointed in 2024, Mr. Slachta previously served as Divisional Vice President of Global Operations and Supply Chain for Molecular Diagnostics at Abbott.

Dave Vort – Chief Commercial Officer. Joined Cytovale in February 2025, bringing extensive experience in commercial strategy and operations within the medical diagnostics industry.

Leadership Changes

In 2024, Cytovale appointed Christopher Slachta as Chief Operating Officer to support the company's rapid growth and commercialization efforts. In February 2025, Dave Vort joined as Chief Commercial Officer to further enhance the company's market expansion strategies.

Competitor Profile

Market Insights and Dynamics

The sepsis diagnostics market is experiencing significant growth due to the high prevalence of sepsis and the critical need for rapid detection methods. Sepsis accounts for over 350,000 deaths annually in the U.S., making it a substantial burden on the healthcare system.

Competitor Analysis

Key competitors in the sepsis diagnostics space include:

Abionic: Developed the IVD Capsule PSP immunoassay, a rapid test for detecting elevated levels of pancreatic stone protein as a marker of sepsis risk, with results in less than 10 minutes.

Inflammatix: Raised $57 million in Series E financing to support regulatory filings and commercialization of its TriVerity Acute Infection and Sepsis Test, which uses real-time RT-LAMP and machine learning algorithms for infection differentiation and disease progression prediction.

Accelerate Diagnostics: Received FDA 510(k) clearance for a blood culture sample preparation platform designed to shorten the time to results for microbial identification tests.

Immunexpress: Commercialized the qPCR-based SeptiCyte Rapid assay for detecting gene expression changes in white blood cells indicative of sepsis.

Strategic Collaborations and Partnerships

Cytovale has established significant partnerships to enhance its market position:

Franciscan Missionaries of Our Lady Health System (FMOLHS): Implemented IntelliSep across multiple hospitals in Louisiana and Mississippi, reporting improved patient outcomes and operational efficiencies.